Vera Grinkevich
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.
Journal: Science advances
Published: June 12, 2026
Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 20, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2026
Multiplexed TrAEL-seq captures DNA replication dynamics in mammalian cells.
Journal: Nucleic acids research
Published: June 19, 2025
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 15, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 27, 2022
POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells.
Journal: Molecular cell
Published: June 06, 2022
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Journal: Nature communications
Published: March 17, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026